Management of Refractory/Relapsed ALL video
The paradigm shift in the management of Refractory/Relapsed Acute Lymphoblastic Leukaemia: what is there beyond chemotherapy?
Speaker: Professor David Marks
David Marks is Professor in Haematology and Stem Cell Transplantation and Director of the Bristol Bone Marrow Transplant (BMT) Unit. He additionally holds Honorary Senior Lectureship at the University of Bristol. He received his medical education at the University of Melbourne, Australia, and his clinical training at the Royal Melbourne Hospital, before undertaking positions in London, UK, and Philadelphia, US. Professor Marks’s research and scientific papers focus on clinical aspects of stem cell transplantation, acute lymphoblastic leukaemia (ALL) and infection. Since 2016, he has been Medical Director of IMPACT, the UK transplant trials platform. He is currently Transplant Coordinator and Deputy Chair of the National Cancer Research Institute ALL working group, Chair of the Adjudication Committee of BSBMT and a member of the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. He has authored numerous scientific papers and chaired the ALL education session at the American Society of Hematology meeting in 2010.
In this video, Professor Marks discusses the goals of treatment and the INO-VATE study with particular reference to the following:
- Key outcomes from the INO-VATE1 study
- Long term follow up2
- How to approach a transplant
- Risk analysis assessment
- Reducing risks of veno-occlusive disease
- Kantarjian HM, et al. New Engl J Med. 2016;375:740-53.
- Kantarjian HM, et al. Cancer 2019;125;2474–2487
PP-INO-GBR-0356. May 2020